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1. Introduction 
First described almost a century ago (Walden, 1914), ionic liquids are a novel class of low 
temperature (typically <100°C) molten salts, comprised of discrete anions and cations 
(Seddon, 1997; Scammells et al., 2005; Stark & Seddon, 2007;).  Many are liquid at room 
temperature.  The majority of room temperature molten ionic liquids are salts with large 
nitrogen or phosphorous-bearing cations with alkyl chain substituents and anions such as 
halides, fluorophosphates, fluoroborates and so on.  Over one million simple ionic liquids 
are theoretically possible, with mixtures of two or more ionic liquids making the 
possibilities for new reaction media almost limitless.  Ionic liquids research has experienced 
a massive upsurge of interest in the past decade, primarily driven by their application in 
‘Green’ chemistry, for example, as replacements for conventional organic solvents and 
volatile organic compounds (VOCs) in the chemical industry. Furthermore, ionic liquids 
have been utilized in multitude of diverse applications from synthetic chemistry 
(separation/extraction/catalysis) to novel biological applications.  The most commonly used 
and extensively described cations and anions employed in ionic liquids are detailed in 
Figure 1 (adapted from Seddon et al, 2000).  
The ability to ‘tune’ the physical, chemical and biological property sets of ionic liquids, by 
independent modification of the properties of the constituent anions and cations, has been 
the major driving force behind the huge interest in this rapidly expanding field of chemistry.  
‘Tuneability’ of ionic liquids introduces an unparalleled flexibility in the design of reagents 
for a particular functional niche, these ‘designer solvents’ (Earle et al., 2006) are capable of 
providing a range of new reaction media potentially having greater diversity of character 
and application than that of the traditional solvents they are designed to replace (Scammells 
et al., 2005; Earle et al., 2006; Stark & Seddon, 2007). A summary of the physicochemical 
properties of common ionic liquids is given in Table 1. Whilst the majority of industry in 
this field has, to date, been directed towards ‘green’ applications, biological issues such as 
stability, biodegradability, recyclability and toxicity (Scammells et al., 2005) have received 
relatively little attention.  However, these issues have attracted increased scrutiny recently, 
and the biological properties of ionic liquids, which in themselves are ‘tuneable’ have 
become one of the most debated topics in the ionic liquids arena. 
Ionic liquids generally have properties such as near-zero vapour pressure (Earle et al., 2006) 
and thermal stability (Kosmulski et al., 2004). However, by altering the cation and anion, 
ionic liquids can be specifically created for a purpose or to possess particular properties 
suited to a given functional niche, and can therefore be described as tunable or designer  
 
www.intechopen.com







Fig. 1. Examples of the most commonly described ionic liquid cations and anions (Adapted 
from Seddon et al., 2000). 
chemicals (Freemantle, 1998; Davis, 2004). Ionic liquids have been validated as ideal 
replacements for organic solvents in a plethora of chemical processes (Villiagran et al., 2006; 
Huddleston et al., 2001; Mizuuchi et al., 2008). Perhaps one of the most attractive 
characteristics of employing ionic liquids in chemical processes is their potential for 
improving reaction yields, facilitating product recovery and their recyclability without loss 
of functionality. As a result ionic liquids have found applicability in an impressively diverse 
range of uses. 
www.intechopen.com
Antimicrobial Ionic Liquids   
 
589 
Physiochemical property Ionic liquid 
Conductivity Good ionic conductivity compared to 
organic solvents/electrolyte systems. This is 
inversely linked to viscosity (Endres & 
Abedin, 2006) 
Viscosity Generally more viscous than common 
molecular solvents.  Viscosity is determined 
by van der Waals forces and hydrogen 
bonding and alkyl chain length in the cation 
(Endres & Abedin, 2006) 
Density Generally more dense than water  (Endres 
and Abedin, 2006) 
Melting point <100°C 
Solubility Ionic liquids can act as both hydrogen bond 
acceptors (anion) and donors (cation) and 
therefore interact with substances with both 
accepting and donating sites (Dupont & 
Suarez, 2006).  Ionic liquids can be divided 
into two groups (water-miscible and water-
immiscible) according to their solubility in 
water (Wei & Ivaska, 2008). Examples of 




methylsulfonyl)imide. Examples of water-
miscible ionic liquids include [1-Butyl-3-
methylimidazolium tetrafluoroborate. (Wei 
and Ivaska, 2008). Miscibility of ionic 
liquids in water is primarily dependent on 
the anion present it is also dependent on the 
structure of the  cation (Seddon et al., 2000; 
Wei & Ivaska, 2008), 
Thermal stability Highly thermally stable (some up to 
temperatures of 450°C) (Endres & Abedin, 
2006) 
Chemical stability Most are stable towards organic and 
inorganic substances (Dupont & Suarez, 
2006) 
Electrochemical window (defined as the 
electrochemical potential range over 
which the electrolyte is neither reduced or 
oxidised at an electrode) 
Wide electrochemical window (Endres & 
Abedin, 2006) 
Table 1. Physiochemical properties of Ionic liquids 
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2. Ionic liquids in ‘green chemistry’ 
Green chemistry is defined as the design of chemical products and processes which reduce 
or eliminate the use and generation of hazardous substances (Anastas & Warner, 1998; 
Seddon et al., 2005). The design of safe and environmentally benign solvents has become 
increasingly important in the development of clean manufacturing processes. Conventional 
organic solvents are often toxic, flammable and volatile which when released into the 
environment can have potentially devastating effects. Ionic liquids have offered promise as 
reagents, which have the potential to replace many hazardous volatile organic solvents 
(including those banned by the Montreal protocol of 1989) (Anastas & Warner, 1998), and 
have therefore been cited as an important element of green chemistry.  Ionic liquids have 
also been shown to have similar (if not superior and more diverse) properties to the 
organic/aqueous solvents they could potentially replace (Visser et al., 2000), whilst having 
negligible vapour pressure thus reducing the likely risk of atmospheric pollution (Fredlake 
et al., 2004).  Attractive physicochemical attributes, improved reaction rates and yields, 
recyclability and design of ionic liquids lacking inherent biological toxicity all represent 
approaches for the ‘greening’ of chemical processes by ionic liquids.    
Ionic liquids have already been reported as alternative ‘green’ solvents for a wide range of 
reactions (Wasserscheid et al., 2002; Prasad et al., 2005; Tao et al., 2006), however, in addition 
to possible concerns about the recyclability of ionic liquids there have also been concerns 
raised over the biodegradability or environmental persistence of ionic liquids (Garcia et al., 
2004; Garcia et al., 2005; Stolte et al., 2008). A series of imidazolium compounds were shown 
to be poorly biodegradable and it was found that bacteria did not use them as a source of 
carbon under the conditions of the investigation (Romero et al., 2008), making them 
potentially persistent polluters. In this study, it was also demonstrated that imidazolium 
based ionic liquids have a wide range of toxicities in this relevant bioassay. Generally, 
toxicity (EC50 value) was found to correlate directly with the length of the n-alkyl 
substituent in the methylimidazolium cation, while the anion has no apparent effect on the 
EC50 value. The authors conclude that the ionic liquids tested are more toxic than 
conventional organic solvents.  In tests against Vibrio fischeri and mammalian cell lines, a 
series of imidazolium ionic liquids of varying alkyl chain length were shown to exhibit 
significant toxicity (Ranke et al., 2004), once again dependent on the length of the cationic n-
alkyl substituent.  
Many ionic liquids are water-soluble and as such could contribute to pollution of aquatic 
environments. For example, it has been demonstrated that imidazolium, pyridinium and 
pyrrolidinium ionic liquids had LC50 > 100 mg/L against Danio rero (zebra fish), and as such 
can be regarded as non-lethal (Pretti et al., 2006).  On the other hand, however, the ammonium 
based ionic liquids had LC50 values remarkably lower than that reported for organic solvents 
and yet proved fatal when zebrafish were exposed to them.  Ecotoxicological tests on several 
ionic liquids have revealed that imidazolium and pyridinium ionic liquids exhibit significant 
toxicity towards the freshwater algae Pseudokirchneriella subcapitata (Pham et al., 2008), while 
imidazolium ionic liquids are toxic to the freshwater crustacean Daphnia magna (Wells & 
Coombe et al., 2004) and Caenorhabditis elegans (Swatloski et al., 2004). A number of recent 
studies have also demonstrated the potential of certain ionic liquids to exhibit excellent 
antimicrobial activity, discussed below, thus presenting the exciting possibility that ionic 
liquids could have application as biocidal agents in the control of microorganisms in the 
environment for contamination and infection control. 
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3. Methods for evaluating the antimicrobial activity of ionic liquids 
A number of methods exist for the accurate determination of microbial susceptibility to 
antimicrobial/antibiotic compounds.  Such methods yield vital data regarding fundamental 
sensitivity or tolerance to a given antimicrobial biocide or antibiotic and are therefore vital 
to the successful treatment and management of microbial infections.  Furthermore, such 
tests are useful for determining relative potency of an antimicrobial agent across a range of 
species and for identifying antimicrobial synergies. The basic testing procedures, which 
have been used in the assessment of the antimicrobial activity of ionic liquids are considered 
briefly below. Whilst the majority of these tests have relied on basic planktonic susceptibility 
assays (minimum inhibitory concentrations (MIC) or minimum bactericidal/fungicidal 
concentration (MBC/MFC)) or agar diffusion techniques, the importance of evaluation of 
antimicrobial activity against microbial biofilms is also discussed.  In our group, we have 
pioneered the use of high throughput screening of ionic liquids against clinically relevant 
microorganisms grown as biofilms, by determination of minimum biofilm eradication 
concentration (MBEC) (Carson et al., 2009; Busetti et al., 2010). 
3.1 Agar diffusion tests 
The agar diffusion technique (also known as the Kirby-Bauer test (Bauer et al., 1966) but 
described somewhat earlier by Abraham am co-workers in 1941 (Abraham et al., 1941)) is a 
simple and commonly employed technique for determination of MIC on solid media. The 
basic method requires antibiotic/biocide impregnated discs to be placed on the surface of 
agar plates seeded or spread with the appropriate test strain of bacteria or fungi.  
Antimicrobial agent(s) may also be added (as a solution) to wells punched in the agar.  The 
diffusion of antimicrobial agent into the surrounding agar results in inhibition of growth 
around the reservoir/source and gives rise to zones or clearance where (for sensitive 
organisms) microbial growth is inhibited. Generally, the diameter of these zones of 
inhibition or clearance increases with increasing concentration of antimicrobial agent, and 
this may be measured to determine qualitatively the relative degree of toxicity. The MIC 
may also be determined from the zero intercept of a linear regression of the squared size of 
these zones of inhibition, x, versus the natural logarithm of the antibiotic concentration 
(Bonov et al, 2008). This is described in the equation below, where D is the diffusion 
coefficient (assumed to be independent of concentration) and t the time over which 




The technique is also useful for empirical determination of antimicrobial activity of a given 
compound or assessing relative antimicrobial potency by measuring zones of inhibition of 
bacterial or fungal growth around the antimicrobial site of application. Recently, this 
method has been championed by Stephens and co-workers (Rebros et al., 2009; Wood & 
Stephens, 2010) as a simple method for rapid determination of relative toxicity of ionic 
liquids.  This simple, inexpensive method has been suggested as a basic requirement in the 
toxicological assessment of ionic liquids and, since it requires neither specialist equipment 
nor advanced microbiological techniques, may be performed routinely in laboratories 
conducting research into ionic liquids with minimum microbiological expertise. However, 
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the method is not without inherent limitations and consequently, care must be taken in 
interpretation of the data obtained.  For example, it is well established that some antibiotics 
deviate from the behaviour described above by interacting with components of the growth 
media; similar effects might be expected with some ionic liquids especially those having 
hydrophobic or amphipathic character. Interaction of ionic liquids and other ionic 
components of the growth media (dissolved salts, nutrients etc.), chemical reactivity of the 
reagent and interaction with the agar itself may all result in erroneous data.  Furthermore, 
the method is unlikely to be of any practical use for ionic liquids which are immiscible with 
water, since agar is >98% water, and thus water miscibility will have a significant effect on 
the extent of diffusion through the medium.  Despite this, the use of agar diffusion assays 
will provide basic toxicity information for a large number of ionic liquids and provides a 
rapid, high-throughput ‘first look’ in the hierarchical screening of antimicrobial activity of 
ionic liquids. 
3.2 Dilution tests 
Dilution tests are routinely used for the determination of the two most fundamental 
parameters in antimicrobial susceptibility testing; the minimum biofilm eradication 
concentration (MIC) and the minimum bactericidal/fungicidal concentration (MBC/MFC), 
sometimes referred to as the minimum lethal concentration (MLC).  Dilution tests usually 
involve the use of liquid media but agar may also be used (as discussed above).  Doubling 
dilutions of the antimicrobial agent are prepared and added to a defined inoculum of test 
microorganism taken from the logarithmic phase of growth, such that a final inoculum of 5 
x 105 colony forming units (CFU or viable cells)/ml is achieved.  Following incubation at 
35ºC ± 2.5ºC overnight (18 hours), the MIC is determined as the concentration of 
antimicrobial contained in the first clear tube/well. Therefore the MIC is defined as the 
minimum concentration of antimicrobial agent that inhibits the growth of an overnight 
culture of microorganism.  The conditions used for the test and appropriate control tests 
(which must be included) are most commonly obtained either from the Clinical and 
Laboratory Standards Institue (CLSI) formerly the National Committee for Clinical 
Laboratory Standard (NCCLS) (NCCLS document M27-A, 1997; NCCLS document M7-A5) 
or the British Society for Antimicrobial Chemotherapy (Andrews, 2001). 
The MBC is the lowest concentration (in mg/L) of antimicrobial that results in ≥99.9% 
killing of the bacterium under test. The 99.9% cut-off is an arbitrary in vitro value with 95% 
confidence limits that has uncertain clinical relevance.  MBCs are determined by spreading 
0.1-ml (100-ml) volumes of all clear (no growth) tubes from a dilution MIC test onto separate 
agar plates (residual antimicrobial in the 0.1-ml sample is ‘diluted’ out over the plate). After 
incubation at 35°C overnight (or longer for slow-growing bacteria), the numbers of colonies 
growing on each plate are recorded. The first concentration of drug that produces <50 
colonies after subculture is considered the MBC. Minimum fungicidal concentrations are 
determined in the same manner, however, different growth media is necessary (e.g. use of 
RPMI 1640 plus 2% dextrose) and the inoculum density (yeast cells or spores) is reduced (c. 
104 CFU/ml). 
3.3 Evaluating biofilm susceptibility to antimicrobial agents  
Both the MIC and MBC/MFC evaluations are suspension tests, which test the susceptibility 
of planktonic (free floating) microorganisms grown under optimum conditions to a given 
www.intechopen.com
Antimicrobial Ionic Liquids   
 
593 
antimicrobial challenge. However, evaluation of the antimicrobial susceptibility of microbial 
biofilms is now recognized as a more physiologically relevant assay. A biofilm may be 
defined as ‘a microbially derived sessile community characterized by cells that are irreversibly 
attached to a substratum or interface or to each other, are embedded in a matrix of extracellular 
polymeric substances that they have produced and exhibit altered phenotype with respect to growth 
rate and gene transcription’ (Donlan & Costerton, 2002).  Biofilms represent the predominant 
mode of growth of microorganisms and also the most persistent, phentypically resistant 
mode of growth, with increased tolerance to antimicrobial challenge. Irrespective of site, 
biofilm formation follows a series of discreet events, summarized below in Figure 2. 
 
 
Fig. 2. Microbial Surface Colonisation; Main Stages in Surface attachment and biofilm 
formation (Adapted from Harrison et al., 2005) 
As the importance of microbial biofilms in medicine, industry and agriculture has become 
clear, a huge amount of industry has been invested into studying their growth and control.  
As a result of this a number of in vitro models have been developed to facilitate elucidation 
of the mechanisms central to this important microbiological process. Each model has relative 
advantages and disadvantages, depending on the aspect of biofilm physiology the models 
were designed study.  These are expertly reviewed in (McBain, 2009; Coeyne & Nelis, 2010).  
However, to date the only model used for the study of biofilm susceptibility of ionic liquids 
is that employed in our group, namely the Calgary Biofilm Device (commercially available 
from Innovotech Inc., Edmonton, AB, Canada as the MBEC Assay). The MBEC assay, 
developed in 1999 by Ceri and co-workers (Ceri et al., 1999) was developed specifically to 
evaluate biofilm susceptibility to antimicrobials.  Essentially, the device consists of a 96-well 
plate and a lid bearing 96 polycarbonate pegs, each peg protrudes into the 96 wells and 
provides a surface onto which the bacteria/fungi may attach and form a biofilm, as shown 
below in Figure 3.   
Shear forces (provided by gyration of the plate) stimulates microbial attachment and biofilm 
formation, the density of which may be determined by sonication of the biofilm back into 
fresh growth media followed by enumeration via standard plate counting. Biofilms grown 
on pegs may then be transferred to a 96-well challenge plate, set up in the same manner as 
an MIC assay with varying concentrations of antimicrobial agent(s) alone or in combination.  
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Fig. 3. The commercially available Calgary Biofilm Device/MBEC Assay Plate 
Following antimicrobial exposure bacteria would again be sonicated from the pegs and 
counted to determine the biofilm MIC (BMIC), biofilm bactericidal concentration (BMBC) 
and biofilm eradication concentration (MBEC) in a highly standardized and reproducible 
assay based on existing MIC technology. 
4. Antimicrobial and antibiofilm activities of ionic liquids 
The toxicity shown in the studies highlighted previously raises issues over the validity of 
the classification of ionic liquids as ‘green’ compounds. However, toxicity itself a tuneable 
property which may be of utility in a number of other applications, for example, in the 
development of antiseptics, disinfectants and anti-fouling reagents (Pernak et al., 2004a; 
Pernak et al., 2004b; Pernak et al., 2007a; Fischmeister et al., 2007).  The antimicrobial 
activities of five new groups of choline-like quaternary ammonium chloride ionic liquids 
were evaluated against a range of Gram positive and Gram negative bacteria (Pernak & 
Chwala, 2003).  The ionic liquids tested all showed good antimicrobial activity, and 
confirmed that lipophlicity was the main factor in determining antimicrobial activity. 
Compounds with an alkyl chain substituent of 12 carbon atoms on the cation all exhibited 
the highest antimicrobial activity across all groups of ionic liquids tested, for a range of test 
microorganisms. 
In a similar study, a series of 3-alkoxymethyl-1-methylimidazolium ionic liquids bearing 
[Cl], [BF4] and [PF6] anions were tested against a range of bacterial species, as well as fungi 
(Pernak et al., 2003). This study demonstrated that shorter cationic alkyl chain substituents 
resulted in reduced antimicrobial activity compared to the imidazolium compounds 
containing 10, 11, 12 and 14 carbon atoms in their alkoxy group, confirming earlier findings 
(Pernak et al., 2004a). Again, the imidazolium ionic liquids with alkoxy substituents of 
twelve carbon atoms were the most active against the bacteria and fungi tested. Another 
study showed that 1, 3 - (dialkloxymethyl)-substituted imidazolium ionic liquids (Pernak et 
al., 2004b) also exhibited broad-spectrum antimicrobial activity against various bacterial 
rods, cocci and fungi. 
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Pyrrolidinium ionic liquids with varying alkyl chain substituents were shown to possess 
good antimicrobial activity against rods, cocci and fungi (Demberelnyamba et al., 2004).  
Compounds exhibiting the greatest antimicrobial activity were those having 14 carbon 
atoms in the alkyl chain. In a recent study, Pernak and co-workers tested a range of 
trigeminal tricationic ionic liquids for antimicrobial activity (Pernak et al., 2007b), it was 
found that, in addition to their broad spectrum antimicrobial activity, their potency was 
much better than the commercially available benzalkonium chloride. A further study on 
chiral ammonium-based ionic liquids (Pernak & Feder-Kubis, 2005) revealed that 
compounds with 11 carbons in the alkyl substituent showed the most activity against a 
range of bacteria and fungi.  In a study carried out on a number of ionic liquids with varying 
anions (Docherty & Kulpa, 2005), it was found that improved antimicrobial activity resulted 
from increasing alkyl group chain length as well as increasing the number of alkyl groups 
substituted on the cation ring. Varying the anion present in the compound did not 
significantly alter toxicity.  Recently, the antimicrobial activity of multifunctional long-alkyl-
chain quaternary ammonium azolate based ionic liquids has been described (Walkiewicz et 
al., 2010). These ionic liquids, based on didecylmethylammonium, benzalkonium, domiphen 
and hexadecyltrimethlammonium cations combined with benzotriazole, 1,2,4-triazolate, 4-
nitroimidazolate or 2-methyl-4-nitroimidazolate anions all exhibited excellent, broad 
spectrum anti-bacterial and antifungal activity, which was comparable or superior to that of 
the original benzalkonium chloride (Walkiewicz et al., 2010). 
According to the studies discussed above, a general feature common to the ionic liquids is a 
dependency on substituent alkyl chain length for antimicrobial potency, indicating a general 
mechanism for antimicrobial activity. Other studies have indicated that the mechanism of 
antimicrobial activity of ionic liquids is via membrane disruption. This seems likely given 
the structural similarity between ionic liquids and antimicrobial agents whose mechanism is 
more fully elucidated (Li et al., 1998; Pernak et al., 2001).  Many ionic liquids have a similar 
structure to cationic surfactants whose primary mode of action membrane-bound protein 
disruption (Bernot et al., 2005).  Another suggested mechanism of toxicity and antimicrobial 
activity is the inhibition of the enzyme acetylcholinesterase, as illustrated in studies of the 
inhibitory effects of imidazolium and pyridinium ionic liquids which were shown to inhibit 
purified enzyme with EC50 levels as low as 13 µM (Stock et al., 2004).   
4.1 Antibiofilm activity of 1-alkyl-3-methylimidazolium chloride and 1-alkylquinolinium 
bromide ionic liquids 
All microbiological toxicity studies conducted to date have described antimicrobial activity 
against planktonic, or free swimming, microbial phenotypes. However, the predominant 
mode of growth of both pathogenic and environmental microorganisms, is as highly-
ordered surface-adhered communities encased within a self-produced protective 
extracellular polymeric matrix (glycocalyx), collectively known as a biofilm (Donlan & 
Costerton, 2002; Hall-Stoodley et al., 2004). A general characteristic of biofilm communities 
is that they tend to exhibit significant tolerance/resistance to antibiotics and 
antimicrobial/biocidal challenge compared with planktonic bacteria of the same species 
(Ceri et al., 1999; Stewart & Costerton, 2001; Gilbert et al., 2002; Stewart, 2002). Therefore, 
significant limitations exist when attempting to extrapolate planktonic culture susceptibility 
data to environmental or clinical scenarios where the majority of microbial growth is as 
biofilms. This is illustrated by the NIH estimation that up to 80% of all chronic human 
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infections are biofilm-mediated and that 99.9% of bacteria in aquatic ecosystems live as 
biofilm communities (Lewis, 2001; Costerton & Wilson, 2004). Indeed, it has been 
demonstrated that there is often no correlation between planktonic susceptibility to 
antimicrobials (MIC values) and biofilm susceptibility of the same species and strain to 
those same antimicrobial agents (Smith et al., 2003).   
Biofilms are a major survival strategy for microbial populations in the face of environmental 
stresses and have been linked to a host of industrially and clinically relevant complications; 
from chronic plant, animal and human infections, to failure of implanted medical devices 
and microbially-influenced biocorrosion. Therefore, knowledge of the antibiofilm activity of 
ionic liquids is both environmentally and clinically relevant.  
In a recent study, Carson and colleagues reported for the first time the in vitro antibiofilm 
activity of a library of 1-alkyl-3-methylimidazolium chloride ionic liquids (the general 
structure is given below in Figure 4) against a panel of clinically relevant pathogenic 
bacteria (including MRSA) and fungi using the Calgary Biofilm Device (CBD), a high-
throughput micro-titre plate-based technology for screening antimicrobial susceptibility of 
microbial biofilms, which permits the determination of minimum biofilm eradication 
concentration (MBEC), or the concentration of an antimicrobial agent required to kill a 
microbial biofilm. This study illustrated that antibiofilm activity of these ionic liquids was 
also dependent on alkyl chain length, with the MBEC value decreasing (increased 
antibiofilm potency) with increasing alkyl chain length. Ionic liquids [Cnmim]Cl where n ≥ 
10 exhibited potent, broad spectrum antimicrobial activity. In general, of the compounds 
tested in this series, [Cnmim]Cl where n = 14, exhibited greatest antibiofilm activity against 
all microbial biofilms. The data from this study indicate that Gram positive microbial 
biofilms (in keeping with planktonic cultures) are generally more susceptible to 
1-alkylmethylimidazolium ionic liquids than Gram negative bacterial biofilms, whilst 
Candida tropicalis biofilms exhibited a similar susceptibility profile to these reagents as the 
representative Gram positive organisms tested in this study (Carson et al., 2009).   
 
 
Fig. 4. General structure of 1-alkyl-3-methylimidazolium chlorides [Cnmim]Cl which 
exhibited antibiofilm activity across a range of clinically relevant pathogens. 
In a further study from the same group, Busetti and co-workers, described the antimicrobial 
and antibiofilm activities of a range of 1-alkylquinolinium bromide ionic liquids (Busetti et 
al., 2010).  In general, these ionic liquids are the most potent antibiofilm ionic liquids tested 
so far, having a superior microbiological toxicity to the 1-alkyl-3-methylimidazolium ionic 
liquids against both planktonic and biofilm cultures of a range of bacteria and fungi 
commonly implicated in nosocomial and device associated infections, including 
Staphylococcus epidermidis, Pseudomonas aeruginosa, Klebsiella aerogenes and Bacillus cereus.  In 
keeping with the observations from our previous studies, the antimicrobial activity is 
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dependent on the length of alkyl chain substituent, with compounds having alkyl chain 
lengths of 12-14 carbon atoms exhibiting greatest antimicrobial potency. The general 
structure of the 1-alkylquinolinium bromides is given below in Figure 5. 
 
 
Fig. 5. General structure of 1-alkylquinolinium bromides with demonstrated antimicrobial 
and antibiofilm activities 
These important studies not only highlight the potential environmental effects of ionic 
liquids to the microbial ecosystem (which are susceptible to their antimicrobial activities 
even in their predominant environmental mode of growth as biofilms) but also opens up the 
real possibility of employing ionic liquids for a plethora of beneficial uses as antimicrobials 
in disinfectants, preservatives, antiseptics and development of anti-infective medical device 
surfaces for use in healthcare and as antibiofouling reagents for a host of industrial 
applications.   
The challenges that remain in bringing the first ionic liquid based biocides to the clinical 
setting as either disinfectants, antiseptics, sterilants for medical devices/instruments or 
preservatives include demonstrating suitably rapid rates of kill, for example high level 
disinfectants would typically be required to be sporocidal in <7 minutes, and (as an industry 
‘rule of thumb’) reduce the original (vegetative) bioburden of 5 microbial species by 5 log 
reductions (99.999% kill) within 5 minutes. The factors that attenuate the activity of ionic 
liquids as disinfectants have not, as yet, received sufficient attention.  Furthermore, the 
toxicological profile of these compounds is, for the present, not elucidated (although 
ongoing work in our laboratory is aimed at addressing this lacuna in our knowledge).  
Despite this, ionic liquids appear to hold great promise in the future development of 
biocides for use in clinical and industrial infection and contamination control.   
5.0 Potential regulatory challenges to antimicrobial applications of ionic 
liquids 
As with all novel compounds with potential application as biocidal products, legislative and 
commercial barriers to their entry to the market exist.  In the following sections, the current 
European legislation regarding biocidal products and new chemical entities coming onto the 
EU market are discussed. These legislative instruments are necessary in safeguarding public 
safety and will no doubt prove burdensome in bringing ionic liquids from the bench to 
various in-use settings where we predict they will be usefully employed as biocides. 
5.1 The Biocidal Products Directive (98/8/EC) 
Directive 98/8/EC of the European Parliament and of the Council on the placing on the 
market of biocidal products was adopted in 1998. The Biocidal Products Directive aims to 
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harmonise both the issues of biocide manufacture and use, and the European market for 
biocidal products.  Furthermore, the directive aims to provide a high level of protection for 
humans, animals and the environment.  The scope of the directive is wide, covering some 23 
different product types including disinfectants (classified by use in given areas), chemicals 
for preservation of products and material (such as timber), non-agricultural pesticides and 
anti-fouling agents used to prevent hull-fouling on vessels. However, medicines and 
cosmetics fall outside the remit of the directive, potentially allowing ionic liquids to be used 
as preservatives in the first instance.  
The basic objective of the directive is to produce a list of active biocidal products that are 
licensed for use across all member states, known as ‘Annex I’. Active substances must be 
assessed and any decision on their inclusion in Annex I will be taken at Community level.  
Only products containing active substances listed in Annex I will be authorised for use in 
the EC. The two-tier system mandated by the directive requires that firstly, active 
substances must be assessed and a decision reached as to their suitability for inclusion in 
Annex I and secondly, the producers and formulators responsible for the placing of the 
market of the biocidal products and their active substances must apply for authorisation of 
the biocidal product.  In each member state, it is the responsibility of the national competent 
authority (in the GB this is the Health and Safety Executive) to authorise products 
containing active substances included in Annex I. The principle of mutual recognition 
outlined in Article 4 of the directive means that once a product containing an Annex I active 
substance has been authorised by one member state it can be recognised in as an authorised 
product in other member states. 
The legislation related to the directive came into force in September 2000, with guidance on 
deadlines for identification and notification of active substances. In June 2009, based on 
experience of working under Directive 98/8/EC, the European Commission adopted a 
proposal for a Regulation concerning the placing on the market and use of biocidal products 
(COM(2009)267), which is intended as a full revision of the existing directive which it will 
repeal and replace.  This revision is a response to a 2008 report on the implementation of the 
directive, which highlighted the inherent weaknesses of the original directive, primarily the 
complexity of the legal framework and the high costs associated with compliance (especially 
the cost of compiling a dossier in support of inclusion of an active substance in Annex I).  
The proposed new regulation is scheduled to enter into force on January 1st 2013. 
Although there is unlikely to be any direct impact on the pharmaceutical industry per se, the 
biocidal products directive and proposed revision is likely to present a significant restriction to 
bringing new disinfectants to market. This is likely to have some impact on the use of new ionic 
liquids for biocidal applications. The experience under the original directive indicated that 
expense was a major issue in supporting the addition of an active substance to Annex I.  It 
remains to be seen if the revised regulation will streamline the process and reduce costs 
associated. 
5.2 Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) 
EC Regulation (EC1907/2006) Registration, Evaluation, Authorisation and Restriction of 
Chemicals (REACH) entered into force on June 1st 2007, replacing a number of European 
Directives and Regulations within a single legislative framework.  The former EC legislative 
framework for chemical substances was a collection of numerous different directives and 
regulations, which had developed historically. Part of the problem, which REACH sought to 
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address, was the different rules governing ‘existing’ and ‘new’ chemicals.  This distinction 
between existing and new chemical substances was introduced under regulation (EC) 
793/93 based on a cut-off date of 1981.  Chemical substances which were reported as being 
on the EC market between 1st January 1971 and 18th September 1981 were called ‘existing’ 
chemicals (~100,000, listed in the European Inventory of Existing Commercial Chemical 
Substances (EINECS)); those introduced to the market after the cut-off date were classified 
as ‘new’ chemicals (~3800). Whilst new chemicals must undergo rigorous testing before 
being placed on the market, there were no such regulations for existing chemicals, as a result 
there is generally insufficient publically accessible information available to accurately assess 
and control these substances effectively. 
Further issues which led to the drafting of this Regulation include the pre-REACH 
allocation of responsibilities whereby public authorities were responsible for undertaking 
risk assessments of substances, with no such responsibilities on downstream users 
(manufacturers, importers, end users). Manufacturers and importers were required to 
provide information on use of the substances, but downstream users (industrial users, 
formulators) were not. In addition, the threshold for notification and testing of new 
chemical substances could be as low as 10 kg per year. This has been regarded as a 
significant barrier to innovation within the EU chemical industry, since the resultant trend 
has been away from developing new chemicals and towards using exiting agents. 
The aims of REACH are: 
i. To provide a high level of protection of human health and the environment from the 
use of chemicals 
ii. To give those who place chemical substances on the market (manufacturers and 
importers) responsibility for understancing and managing the risks associated with 
their use 
iii. To allow free movement of substances on the EU market 
iv. To enhance the innovation in and competitiveness of the EU chemicals industry 
v. To promote the use of alternative methods (other than animal studies) for assessment of 
hazardous properties of substances, e.g. QSAR studies. 
REACH is based on the concept that the chemical industry itself is best placed to ensure that 
chemicals placed on the market in the EU do not adversely affect human health or the 
environment. REACH creates a single system for both new and existing chemical 
substances. Substances are now described as ‘non-phase-in’ substances (i.e. those not 
produced or marketed prior to the entry into force of REACH) and ‘phase-in’ substances (i.e. 
those substances listed in EINECS, or those that have been manufactured in the Community, 
but not placed on the Community market, in the last 15 years or the so called “no longer 
polymers” of Directive 67/548). A major part of REACH is the requirement for 
manufacturers or importers of substances to register them with a central European 
Chemicals Agency (ECHA), with a standard set of data to be submitted for each substance.  
If the substance is not registered, data will not be available and the substance will no longer 
be able to be legally manufactured or supplied.  
REACH proposes a number of benefits over the existing patchwork of legislation and 
regulations. Primarily, by creating parity for ‘existing’ and ‘new’ chemical substances with 
respect to risk management and the making available of data for all substances in relation to 
this. Furthermore, it simplifies the existing EU level regulation by replacing 40 existing 
pieces of legislation and creates a single system for all chemicals, removing the distinction of 
www.intechopen.com
 Ionic Liquids: Applications and Perspectives 
 
600 
‘existing’ and ‘new’ substances. REACH will result in better risk characterisation of 
chemicals and mandates improved information flows in the supply chain.  REACH will 
close the knowledge gap for over 30,000 existing substances, providing information on both 
acute and long-term toxicity.  REACH provisions are intended to be phased in over a period 
of 11 years. Manufacturers of biocides and biocidal products are examining closely the likely 
impact of REACH and it is generally regarded that REACH will impose a significant 
burden, but one which must be borne for commercial reasons.  In this respect, the bringing 
onto the market of ionic liquid based biocidal products will require (i) demonstration that 
these reagents are more effective or have superior properties and in-use characteristics 
compared with existing biocides and (ii) significant financial investment to satisfy the 
compliance programmes required by REACH.  That said, there exists a pressing need for 
new and effective biocides, in the face of increasing emergence of resistance to most 
conventional biocides. Ionic liquids have numerous attractive properties, which render them 
excellent candidates for biocidal applications, and, to date, no reports of resistance have 
been published. 
6. Conclusion 
Since ionic liquids are tunable and designer chemicals, they have been used in a wide 
variety of applications. Many have been developed for use as solvents in industrial 
chemistry, and generally their use confers a number of advantages over using other 
solvents; superior reaction rates, recyclability of reactants and catalysts and improved 
product recovery. Having negligible vapour pressure, it has been suggested that ionic 
liquids will not contribute to air pollution and are thus green alternative to conventional 
organic solvents which are generally volatile, flammable and toxic. As a result of this, many 
studies have been conducted on the use of ionic liquids as novel green solvents to replace 
established solvents for particular reactions.  
However, toxicity of ionic liquids has been demonstrated by a number of groups, including 
our own, in a variety of environmental niches, and raises questions over their ‘green’ 
credentials. Nonetheless the toxicity of ionic liquids is in itself a property which can be 
tuned and exploited for other beneficial uses, for example in developing novel 
antimicrobials. We have demonstrated the utility of ionic liquids as antibiofilm agents; 
biofilms are complex, organised communities of bacteria which have been shown to have 
greater tolerance and resistance to antimicrobials, accounting for the majority of chronic and 
acute infections as well as the majority of bacterial communities in aquatic environments.  In 
summary, the biological properties of ionic liquids may yet prove their most exciting and 
the benefits of rationally designed, bespoke ionic liquid-based antimicrobials to human 
health has yet to be harnessed. 
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